New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
04:55 EDTALDR, ALDR, ALDR, ALDR, ALDR, ALDR, CNDO, CNDO, CNDO, CNDO, CNDO, CNDO, ISIS, ISIS, ISIS, ISIS, ISIS, ISIS, PTCT, PTCT, PTCT, PTCT, PTCT, PTCT, OPXA, OPXA, OPXA, OPXA, OPXA, OPXA, SRPT, SRPT, SRPT, SRPT, SRPT, SRPT, XNPT, XNPT, XNPT, XNPT, XNPT, XNPT, SNY, SNY, SNY, SNY, SNY, SNY, BIIB, BIIB, BIIB, BIIB, BIIB, BIIB, SYN, SYN, SYN, SYN, SYN, SYN, CYTK, CYTK, CYTK, CYTK, CYTK, CYTKAmerican Academy of Neurology to hold annual meeting
66th Annual Meeting of the AAN is being held in Philadelphia on April 26-May 3.
News For CYTK;SYN;BIIB;SNY;XNPT;SRPT;OPXA;PTCT;ISIS;CNDO;ALDR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 20, 2015
06:40 EDTSRPTSarepta upgraded to Buy from Hold at Canaccord
Subscribe for More Information
06:34 EDTSRPTSarepta upgraded to Buy from Neutral at SunTrust
Price target is $33.
May 19, 2015
19:06 EDTSRPTOn The Fly: After Hours Movers
UP AFTER EARNINGS: Computer Sciences (CSC), up 5%... NQ Mobile (NQ), up 1.4%. ALSO HIGHER: Sarepta Therapeutics (SRPT), up 38.9% after announcing plans for rolling eteplirsen NDA... LendingClub (LC), up 2.8% after being upgraded to Overweight from Equal Weight at Morgan Stanley. DOWN AFTER EARNINGS: Keysight Technologies (KEYS), down 3.1%... Autodesk (ADSK), down 2.1%. ALSO LOWER: Cimarex Energy (XEC), down 4% after filing to sell 6M shares of common stock... Norwegian Cruise Line (NCLH), down 2.5% after filing to sell 20M ordinary shares for holders... Achillion Pharmaceuticals (ACHN), down 3.2% following collaboration for HCV with Janssen.
16:11 EDTSRPTSarepta up 36% to $22.28 after announcing plans for rolling eteplirsen NDA
Subscribe for More Information
16:04 EDTSRPTSarepta to submit rolling eteplirsen NDA, sees complete submission by mid-year
Subscribe for More Information
16:02 EDTSRPTSarepta plans to complete Eteplirsen NDA submission by mid-year
16:01 EDTSRPTSarepta says to submit first two components of Eteplirsen NDA this week
Subscribe for More Information
16:01 EDTSRPTSarepta to submit rolling NDA for Eteplirsen following meeting with FDA
Subscribe for More Information
09:32 EDTSYNSynthetic Biologics says C. difficile program on target for Phase 2b trial in 2H
Subscribe for More Information
06:55 EDTSNYGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 18, 2015
12:34 EDTSNYRegeneron, Sanofi announce positive pivotal Phase 2b dupilumab data in asthma
Subscribe for More Information
08:29 EDTALDRAlder Biopharmaceuticals price target raised to $51 from $46 at Bernstein
Subscribe for More Information
May 17, 2015
14:59 EDTSNYL'Oreal CEO 'ready' to sell Sanofi stake if needed, Barron's says
Subscribe for More Information
May 15, 2015
10:29 EDTSNYAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTBIIBAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
May 14, 2015
07:44 EDTALDRInternational Headache Society to hold a conference
17th Congress of the International Headache Society is being held in Valencia, Spain on May 14-17.
May 13, 2015
07:32 EDTBIIBBiogen names Matt Griffiths as CIO
Subscribe for More Information
07:31 EDTSNYHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
07:05 EDTSNYSanofi exercises option on therapeutic program with Selecta Biosciences
Selecta Biosciences., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease. Under the terms of the collaboration, Selecta is eligible to receive research support and several pre-clinical, clinical, regulatory and sales milestones totaling up to $300 million for this new program in celiac disease. Additionally, Selecta is also entitled to up to double digit tiered royalties as percentage of product net sales for any commercialized immunotherapy resulting from these efforts with Sanofi. November 2012, Selecta announced that they had formed a strategic global collaboration to discover highly targeted, antigen-specific immunotherapies for life threatening allergies. Under the agreement, Sanofi obtained a first exclusive license to develop an immunotherapy designed to abate acute immune responses against a life threatening food allergen and an option to develop two additional candidate immunotherapies for allergies and celiac disease. With the exercise of this option by Sanofi, Selecta and Sanofi now have two initiatives actively advancing immune tolerance treatments under the terms of the 2012 agreement. In October 2014, Selecta and JDRF announced another collaboration with Sanofi to research novel antigen-specific immune therapies for Type 1 Diabetes.
May 12, 2015
16:06 EDTOPXAOpexa Therapeutics reports Q1 EPS (12c), consensus (15c)
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use